SCHEMBL7412855

SCHEMBL7412855

CCCCc1ccc(S(=O)(=O)N[C@@H](Cc2ccc(OCCCONC(=N)N)cc2)C(=O)OC(=O)C(F)(F)F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.42
MMP3 P08254 3/20 0.40
MMP13 P45452 3/20 0.40
F2 P00734 4/20 0.40
TMPRSS6 Q8IU80 2/20 0.40
ITGB3 P05106 6/20 0.40
ITGA2B P08514 6/20 0.40
SMN1; SMN2 Q16637 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
MMP2 P08253 3/20 0.37
MMP9 P14780 2/20 0.37
MMP8 P22894 2/20 0.37
MMP1 P03956 2/20 0.37
MMP14 P50281 2/20 0.37
MMP25 Q9NPA2 1/20 0.37
ITGAV P06756 1/20 0.36
CHRM2 P08172 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADAMTS4 O75173 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7413583 0.98 KCNA5 (0.41) KCNA5MMP3MMP13F2TMPRSS6
SCHEMBL7415235 0.97 KCNA5 (0.44) KCNA5MMP3MMP13F2TMPRSS6
SCHEMBL7418524 0.96 F2 (0.43) KCNA5MMP3MMP13F2TMPRSS6
SCHEMBL7694791 0.91 MMP2 (0.45) KCNA5F2TMPRSS6ITGB3ITGA2B
SCHEMBL7416574 0.91 ITGB3 (0.45) KCNA5F2TMPRSS6ITGB3ITGA2B
SCHEMBL7699209 0.90 F2 (0.42) KCNA5MMP13F2TMPRSS6ITGB3
SCHEMBL7418015 0.89 ALDH1A1 (0.46) KCNA5MMP13F2TMPRSS6ITGB3
Trifluoroacetic Acid SCHEMBL7412846 0.89 ITGB3 (0.49) KCNA5MMP3MMP13F2TMPRSS6
SCHEMBL7413464 0.89 F2 (0.42) KCNA5MMP3MMP13F2TMPRSS6
SCHEMBL7414434 0.89 F2 (0.42) KCNA5F2TMPRSS6ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6344484-B1 TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-02-05 US disclosed
EP-1159262-A1 TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-12-05 EP disclosed
WO-2000047552-A1 TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed